INS and obesity disorder: Indeed, similar findings were shown by Yang et al. (2022) which 12 weeks of d‐chiro‐inositol (DCI) (50 and 100 mg/Kg/day, respectively) treatment in mice fed with HFD, attenuated obesity, liver fat accumulation, and glycemic profile (e.g., FBS and insulin levels) by increasing hepatic protein expression levels of phosphorylated‐AMPKα at Thr172.